1887

Journal of General Virology header logo

Volume 84, Issue 12

A novel cellular RNA helicase, RH116, differentially regulates cell growth, programmed cell death and human immunodeficiency virus type 1 replication Free

Abstract

In an effort to define novel cellular factors regulating human immunodeficiency virus type 1 (HIV-1) replication, a differential display analysis has been performed on endogenously infected cells stimulated with the HIV-suppressive immunomodulator Murabutide. In this study, the cloning and identification of a Murabutide-downregulated gene, named RH116, bearing classical motifs that are characteristic of the DExH family of RNA helicases, are reported. The 116 kDa encoded protein shares 99·9 % similarity with MDA-5, an inducible RNA helicase described recently. Ectopic expression of RH116 in HeLa-CD4 cells inhibited cell growth and cell proliferation but had no measurable effect on programmed cell death. RH116 presented steady state cytoplasmic localization and could translocate to the nucleus following HIV-1 infection. Moreover, the endogenous expression of RH116, at both the transcript and protein levels, was found to be considerably upregulated after infection. Overexpression of RH116 in HIV-1-infected HeLa-CD4 cells also resulted in a dramatic increase in the level of secreted viral p24 protein. This enhancement in virus replication did not stem from upregulated proviral DNA levels but correlated with increased unspliced and singly spliced viral mRNA transcripts. These findings implicate RH116 in the regulation of HIV-1 replication and point to an apoptosis-independent role for this novel helicase in inducing cell growth arrest.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.19300-0
2003-12-01
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/12/vir843215.html?itemId=/content/journal/jgv/10.1099/vir.0.19300-0&mimeType=html&fmt=ahah

References

  1. Al-Harthi L., Roebuck K. A. 1998; Human immunodeficiency virus type-1 transcription: role of the 5′-untranslated leader region. Int J Mol Med 1:875–881
     [Google Scholar]
  2. Altschul S. F., Madden T. L., Schaffer A. A., Zhang J., Zhang Z., Miller W., Lipman D. J. 1997; Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389–3402
     [Google Scholar]
  3. Amiel C., Darcissac E., Truong M. J., Dewulf J., Loyens M., Mouton Y., Capron A., Bahr G. M. 1999; Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. J Infect Dis 179:83–91
     [Google Scholar]
  4. Amiel C., de la Tribonnière X., Vidal V., Darcissac E., Mouton Y., Bahr G. M. 2002; Clinical tolerance and immunological effects after single or repeated administrations of the synthetic immunomodulator Murabutide in HIV-1-infected patients. J Acquir Immune Defic Syndr 30:294–305
     [Google Scholar]
  5. Angel J. B. 2001; Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies. AIDS Read 11:209–221
     [Google Scholar]
  6. Bahr G. M. 2003a; Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunomodulator murabutide. J Antimicrob Chemother 51:5–8
     [Google Scholar]
  7. Bahr G. M. 2003b; Immune and antiviral effects of the synthetic immunomodulator Murabutide: molecular basis and clinical potential. In Vaccine Adjuvants: Immunological and Clinical Principles Edited by Hackett C., Harn D. Totowa: Humana Press; (in press)
    [Google Scholar]
  8. Bahr G. M., Darcissac E., Bevec D., Dukor P., Chedid L. 1995; Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide. Int J Immunopharmacol 17:117–131
     [Google Scholar]
  9. Bahr G. M., Darcissac E. C., Casteran N., Amiel C., Cocude C., Truong M. J., Dewulf J., Capron A., Mouton Y. 2001; Selective regulation of human immunodeficiency virus-infected CD4+ lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice. J Virol 75:6941–6952
     [Google Scholar]
  10. Balomenos D., Martinez A. C. 2000; Cell-cycle regulation in immunity, tolerance and autoimmunity. Immunol Today 21:551–555
     [Google Scholar]
  11. Bélec L., Piketty C., Si-Mohamed A., Goujon C., Hallouin M. C., Cotigny S., Weiss L., Kazatchkine M. D. 2000; High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis 181:1808–1812
     [Google Scholar]
  12. Bickmore W. A., Sutherland H. G. 2002; Addressing protein localization within the nucleus. EMBO J 21:1248–1254 erratum 21, 25
    [Google Scholar]
  13. Billaut-Mulot O., Cocude C., Kolesnitchenko V., Truong M. J., Chan E. K., Hachula E., de la Tribonnière X., Capron A., Bahr G. M. 2001a; SS-56, a novel cellular target of autoantibody responses in Sjogren syndrome and systemic lupus erythematosus. J Clin Invest 108:861–869
     [Google Scholar]
  14. Billaut-Mulot O., Idziorek T., Loyens M., Capron A., Bahr G. M. 2001b; Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost. Vaccine 19:2803–2811
     [Google Scholar]
  15. Boden D., Hurley A., Zhang L. 9 other authors 1999; HIV-1 drug resistance in newly infected individuals. JAMA 282:1135–1141
     [Google Scholar]
  16. Chedid L. A., Parant M. A., Audibert F. M., Riveau G. J., Parant F. J., Lederer E., Choay J. P., Lefrancier P. L. 1982; Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect Immun 35:417–424
     [Google Scholar]
  17. Chomel J. J., Simon-Lavoine N., Thouvenot D., Valette M., Choay J., Chedid L., Aymard M. 1988; Prophylactic and therapeutic effects of murabutide in OF1 mice infected with influenza A/H3N2 (A/Texas/1/77) virus. J Biol Response Mod 7:581–586
     [Google Scholar]
  18. Connick E., Lederman M. M., Kotzin B. L. 12 other authors 2000; Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 181:358–363
     [Google Scholar]
  19. Darcissac E. C., Truong M. J., Dewulf J., Mouton Y., Capron A., Bahr G. M. 2000; The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells. J Virol 74:7794–7802
     [Google Scholar]
  20. Flores O., Lee G., Kessler J., Miller M., Schlief W., Tomassini J., Hazuda D. 1999; Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication. Proc Natl Acad Sci U S A 96:7208–7213
     [Google Scholar]
  21. Gandhi R. T., Chen B. K., Straus S. E., Dale J. K., Lenardo M. J., Baltimore D. 1998; HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism. J Exp Med 187:1113–1122
     [Google Scholar]
  22. Glynn J. M., McElligott D. L., Mosier D. E. 1996; Apoptosis induced by HIV infection in H9 T cells is blocked by ICE-family protease inhibition but not by a Fas (CD95) antagonist. J Immunol 157:2754–2758
     [Google Scholar]
  23. Hrimech M., Yao X. J., Bachand F., Rougeau N., Cohen E. A. 1999; Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate–early protein during HIV-1 infection. J Virol 73:4101–4109
     [Google Scholar]
  24. Jankowsky E., Jankowsky A. 2000; The DExH/D protein family database. Nucleic Acids Res 28:333–334
     [Google Scholar]
  25. Kang D. C., Gopalkrishnan R. V., Wu Q., Jankowsky E., Pyle A. M., Fisher P. B. 2002; mda-5 : an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci U S A 99:637–642
     [Google Scholar]
  26. Kovacsovics M., Martinon F., Micheau O., Bodmer J. L., Hofmann K., Tschopp J. 2002; Overexpression of Helicard, a CARD-containing helicase cleaved during apoptosis, accelerates DNA degradation. Curr Biol 12:838–843 erratum 12, 1633
    [Google Scholar]
  27. Li J., Tang H., Mullen T. M., Westberg C., Reddy T. R., Rose D. W., Wong-Staal F. 1999; A role for RNA helicase A in post-transcriptional regulation of HIV type 1. Proc Natl Acad Sci U S A 96:709–714
     [Google Scholar]
  28. Liou L. Y., Herrmann C. H., Rice A. P. 2002; Transient induction of cyclin T1 during human macrophage differentiation regulates human immunodeficiency virus type 1 Tat transactivation function. J Virol 76:10579–10587
     [Google Scholar]
  29. Liu Z. P., Olson E. N. 2002; Suppression of proliferation and cardiomyocyte hypertrophy by CHAMP, a cardiac-specific RNA helicase. Proc Natl Acad Sci U S A 99:2043–2048
     [Google Scholar]
  30. Luking A., Stahl U., Schmidt U. 1998; The protein family of RNA helicases. Crit Rev Biochem Mol Biol 33:259–296
     [Google Scholar]
  31. Mamiya N., Worman H. J. 1999; Hepatitis C virus core protein binds to a DEAD box RNA helicase. J Biol Chem 274:15751–15756
     [Google Scholar]
  32. Morgan D. O. 1997; Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261–291
     [Google Scholar]
  33. Neumann M., Harrison J., Saltarelli M., Hadziyannis E., Erfle V., Felber B. K., Pavlakis G. N. 1994; Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction. AIDS Res Hum Retroviruses 10:1531–1542
     [Google Scholar]
  34. Piatak M. Jr, Luk K. C., Williams B., Lifson J. D. 1993; Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. Biotechniques 14:70–81
     [Google Scholar]
  35. Reddy T. R., Tang H., Xu W., Wong-Staal F. 2000; Sam68, RNA helicase A and Tap cooperate in the post-transcriptional regulation of human immunodeficiency virus and type D retroviral mRNA. Oncogene 19:3570–3575
     [Google Scholar]
  36. Truong M. J., Darcissac E. C., Hermann E., Dewulf J., Capron A., Bahr G. M. 1999; Interleukin-16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and in dendritic cells. J Virol 73:7008–7013
     [Google Scholar]
  37. You L. R., Chen C. M., Yeh T. S., Tsai T. Y., Mai R. T., Lin C. H., Lee Y. H. 1999; Hepatitis C virus core protein interacts with cellular putative RNA helicase. J Virol 73:2841–2853
     [Google Scholar]
  38. Zhang X., Wang C., Schook L. B., Hawken R. J., Rutherford M. S. 2000; An RNA helicase, RHIV-1, induced by porcine reproductive and respiratory syndrome virus (PRRSV) is mapped on porcine chromosome 10q13. Microb Pathog 28:267–278
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.19300-0
Loading
A novel cellular RNA helicase, RH116, differentially regulates cell growth, programmed cell death and human immunodeficiency virus type 1 replication
J. Gen. Virol. 84, 3215 (2003); https://doi.org/10.1099/vir.0.19300-0
/content/journal/jgv/10.1099/vir.0.19300-0
/content/journal/jgv/10.1099/vir.0.19300-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error